Human Recombinant Insulin market Research Report till 2025 with Trends and Forecast

1
GLOBAL MARKET ESTIMATES RESEARCH
CONSULTANTS Ankita Roy, Treesha Banerjee and
Liza Dsouza from Global Market Estimates throw
the spotlight on the growing Human Recombinant
Insulin market Human Recombinant Insulin Market
Insights The Global Human Recombinant Insulin
market is expected to grow at a significant CAGR
during the forecast period. Factors such as
increasing prevalence of diabetes over the world
and rising investment in medical research are
expected to boost growth in the human
recombinant insulin market. Recombinant Insulin
is basically synthetic insulin which is
developed using recombinant DNA technology. This
insulin is produced by harvesting proteins in
the Escherichia coli (E.coli) bacteria. However,
factors such as high cost of recombinant insulin
in the market, lack of awareness about new
technology and risks associated with the use of
recombinant insulin are expected to have a
negative impact on the growth in human
recombinant insulin market.
Human Recombinant Insulin Market Product Type
Insights On the basis of material type, the
Human Recombinant Insulin market can be
classified into Rapid-Acting Human Insulin,
Short-Acting Human Insulin, Intermediate-Acting
Human Insulin, Long-Acting Human Insulin and
Premixed Human Insulin. The long-acting human
insulin segment is projected to hold the largest
market share in terms of revenue in the market
during through the forecast period. This can be
attributed to the ability of long-acting insulin
to control blood sugar levels through the entire
day. This type of insulin is primarily used for
patients with chronic diabetic conditions, in
order to keep it under control. Rapid-acting
insulin is expected to hold the second largest
market share, followed by the premixed human
insulin segment.
2
GLOBAL MARKET ESTIMATES RESEARCH CONSULTANTS
Human Recombinant Insulin Market Distribution
Channel Insights The Global Human Recombinant
Insulin market is segmented into Hospital
Pharmacies, Retail Pharmacies, and Online
Pharmacies based on the distribution channel. The
retail pharmacies segment is forecasted to hold
the major market share followed by the hospital
pharmacies segment. The online pharmacies segment
is projected to grow at the highest CAGR owing
to rising popularity and convenience of online
medicine purchases. Human Recombinant Insulin
Market Brand Insights Based on the brand, the
human recombinant insulin market is classified
into Insuman, Humulin, and Novolin, among
others. Human Recombinant Insulin Market
Regional Insights North America is expected to
hold the largest market share in terms of revenue
in the Human Recombinant Insulin market owing to
growing prevalence of diabetes in the U.S. Rapid
technological advancement and investment in
medical research in diabetes is further expected
to contribute to the growth of human recombinant
insulin market in the region. The Asia Pacific
region is projected to demonstrate rapid growth
in the human recombinant insulin market. This
growth can be attributed to a high diabetic
population in countries such as India, China,
and other developing countries. Growing awareness
about modern medicine is expected to positively
impact the market for human recombinant insulin
in the region.
3
GLOBAL MARKET ESTIMATES RESEARCH
CONSULTANTS Human Recombinant Insulin Market
End-Use Landscape The end-use landscape entails
a list of current and prospective consumers
prevailing across the regions. This section
provides company addresses, contact details,
products, and regional presence of companies who
are purchasing or are likely to purchase
controlled release fertilizer over the coming
years. Some leading consumers of controlled
release fertilizer are LifePoint Health, Prime
Healthcare Services, and Cipla among
others. Human Recombinant Insulin Vendor
Landscape The report contains a chapter
dedicated to vendors operating in the market,
covering raw material manufactures, equipment
developers, manufacturers, and distributors. The
report provides these insights on a regional
level. This section of the report entails contact
details, experience, products manufactured/suppli
ed, and geographical presence of
companies. Human Recombinant Insulin Share
Competitor Analysis Some of the key players
operating in the Human Recombinant Insulin market
are Novo Nordisk A/S, Eli Lilly and Company,
Sanofi S.A., Julphar Gulf Pharmaceutical
Industries, Biocon Limited, Bioton S.A., Gan
Lee Pharmaceuticals, Ltd., Zhuhai United
Laboratories Co., Ltd., Wanbang
Biopharmaceuticals Co., Ltd., and Dongbao
Enterprise Group Co., Ltd. among others. In
June 2018, Eli Lilly and Company came up with a
helpline for providing assistance to patients
who require financial assistance for their
insulin needs. The helpline is called Lily
Diabetes Solution Center. In June 2018, Eli
Lilly and Companys product- Humulin R U-500
showed greater reduction in A1C as compared to
multiple daily injections when administered to
adults with type 2 diabetes. In September 2017,
Biocon Limited received funding from the Juvenile
Diabetes Research Foundation (JDRF) for their
study involving evaluation of the oral insulin
drug Tregopil in patients with type 1 diabetes.
4

• GLOBAL MARKET ESTIMATES RESEARCH CONSULTANTS
• The report segments the Human Recombinant Insulin
  market on the basis of By Product Type
• Rapid-Acting Human Insulin
• Short-Acting Human Insulin
• Intermediate-Acting Human Insulin
• Long-Acting Human Insulin
• Premixed Human Insulin
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Brand
• Insuman

5
GLOBAL MARKET ESTIMATES RESEARCH CONSULTANTS